Sector News

Sandoz to launch five major biosimilars by 2020

June 21, 2016
Life sciences

Novartis unit Sandoz has unveiled plans to launch five biosimilars of major oncology and immunology biologics across key global markets by 2020, potentially broadening access to treatment.

The group says its plan to have a total of eight on the market by then is underpinned by an “aggressive regulatory submissions strategy” of 11 filings over a three-year period through 2017, six of which have already been completed.

Subject to regulatory requirements and approvals, Sandoz’ upcoming launches will include biosimilars of Enbrel (etancercept), Humira (adalumumab), Neulasta (pegfilgrastrim), Remicade (inflximab), and Rituxan (rituximab), which collectively generate annual sales of nearly $44 billion.

The firm will be hoping that its cheaper alternatives, that are clinically comparable and could reportedly be offered at discounts of up to 75 percent in some cases, will steal significant market share from their reference biologics and enable more patients access to treatment.

“Access to medicines remains the single largest unmet healthcare need in developed and developing countries alike,” noted Richard Francis, division head and chief executive of Sandoz.

“Biologics have revolutionised treatment of many disabling and life-threatening diseases but far too many people who need these medicines are not able to access them”.

Greater acceptance of biosimilar medicines in a growing number of therapy areas is expected to deliver total savings of as much as $110 billion to health systems across Europe and the US through 2020, according to research by the IMS Institute for Healthcare Informatics, highlighting their potential.

However, the report does stress that the offer of price cuts alone will not be enough to ensure that biologics fully realise their potential, and that educating physicians, patients and payers will also be critical elements.

Meanwhile, Sandoz also announced that, by 2020, it will have invested some $1 billion into expanding state-of-the-art biomanufacturing facilities at Schaftenau and Kundl, Austria, to secure delivery of its biosimilars to patients around the globe.

By Selina McKee

Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).